In August 2025, Hoffmann-La Roche announced a study is to compare the efficacy and safety of glofitamab in combination with ...

The Peripheral T-cell Lymphoma market report offers information on current treatment methods, new drugs, the market share of different therapies, and the present and projected size of the ...

Peripheral T-cell lymphoma (PTCL) is an aggressive and uncommon type of non-Hodgkin lymphoma. Genetic research has led to improving understanding of disease and thus opened huge opportunities in ...

T cells and/or bispecific antibody (BsAb) has been established and become a promising treatment strategy for ...

10. Peripheral T Cell Lymphomas Therapeutics Assessment 11. Peripheral T Cell Lymphomas Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13.

Peripheral T-cell Lymphoma Drugs Uptake This section focusses on the rate of uptake of the potential drugs that are expected to get launched in the market during the study period 2017–2030.

The link between breast implants and lymphoma is broader than initially believed, results of a cohort study confirmed.Women ...

Five women were diagnosed in the breast contralateral to the primary breast cancer. Zero and five cases reported radiotherapy ...

Peripheral T-cell lymphoma represents a heterogeneous collection of aggressive lymphomas arising from mature T-cells and natural killer cells, comprising approximately 10–15% of all non-Hodgkin ...

e19065Background: Peripheral T-cell Lymphomas (PTCLs) are rare, aggressive lymphoid malignancies with poor outcomes. Comparative data on frontline regimens are limited. This network meta-analysis ...